Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories
Published December 11, 2024 · Recall initiated: November 14, 2024
Summary
FDA records drug Class II recall D-0100-2025, published December 11, 2024 and initiated November 14, 2024. Recalling firm: Amerisource Health Services LLC; Status: Ongoing; Reported quantity: 23,490 bottles; Lot: a) 30 count; Lot, expiry: DT3023019B, DT3023020A, exp 01/31/2025 b) 1000 count; Lot, expiry: DTB23098A, exp 08/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Amerisource Health Services LLC
- Distributor
- PA, OH, PR
- Lot
- a) 30 count; Lot, expiry: DT3023019B, DT3023020A, exp 01/31/2025 b) 1000 count; Lot, expiry: DTB23098A, exp 08/31/2025
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPrimidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by:May 27, 2026
- FDAPrimidone Tablets, USP, 250 mg, 100 Tablets (10 x 10 unit dose blister) per carton, Rx only, Distributed by:May 27, 2026
- FDAMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mgApril 1, 2026
- FDAOxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, TheFebruary 18, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 20 mg, Rx only, 60 count bottles, Manufactured by: Aurobindo PharmaDecember 11, 2024
- FDADuloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottle, Manufactured by: AurobindoDecember 11, 2024
Questions about this recall
Was Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories recalled?
Yes. FDA published recall D-0100-2025 on December 11, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
What should I do if I have this product?
Voluntary: Firm initiated · Letter